Literature DB >> 22193163

Navigating the ERAD interaction network.

Thibault Mayor1.   

Abstract

The endoplasmic reticulum (ER)-associated protein degradation (ERAD) pathway, which orchestrates the degradation of ER proteins by the proteasome, involves a plethora of proteins with diverse functions. Using a combination of proteomic and genetic approaches, a recent study provides fresh insights into the organization of the mammalian ERAD interaction network and the functions of its components.

Entities:  

Mesh：

Year:  2011        PMID： 22193163     DOI： 10.1038/ncb2412

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN： 1465-7392            Impact factor:   28.824


  8 in total

1.  A luminal surveillance complex that selects misfolded glycoproteins for ER-associated degradation.

Authors:  Vladimir Denic; Erin M Quan; Jonathan S Weissman
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

2.  Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins.

Authors:  Pedro Carvalho; Veit Goder; Tom A Rapoport
Journal:  Cell       Date:  2006-07-28       Impact factor: 41.582

3.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

4.  Characterization of an ERAD pathway for nonglycosylated BiP substrates, which require Herp.

Authors:  Yuki Okuda-Shimizu; Linda M Hendershot
Journal:  Mol Cell       Date:  2007-11-30       Impact factor: 17.970

Review 5.  Protein quality control in the ER: balancing the ubiquitin checkbook.

Authors:  Jasper H L Claessen; Lenka Kundrat; Hidde L Ploegh
Journal:  Trends Cell Biol       Date:  2011-11-03       Impact factor: 20.808

Review 6.  One step at a time: endoplasmic reticulum-associated degradation.

Authors:  Shruthi S Vembar; Jeffrey L Brodsky
Journal:  Nat Rev Mol Cell Biol       Date:  2008-11-12       Impact factor: 94.444

7.  Defining human ERAD networks through an integrative mapping strategy.

Authors:  John C Christianson; James A Olzmann; Thomas A Shaler; Mathew E Sowa; Eric J Bennett; Caleb M Richter; Ryan E Tyler; Ethan J Greenblatt; J Wade Harper; Ron R Kopito
Journal:  Nat Cell Biol       Date:  2011-11-27       Impact factor: 28.824

8.  Stringent requirement for HRD1, SEL1L, and OS-9/XTP3-B for disposal of ERAD-LS substrates.

Authors:  Riccardo Bernasconi; Carmela Galli; Verena Calanca; Toshihiro Nakajima; Maurizio Molinari
Journal:  J Cell Biol       Date:  2010-01-25       Impact factor: 10.539
  8 in total
  3 in total

1.  Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Authors:  Christoph Driessen; Marianne Kraus; Markus Joerger; Hilde Rosing; Jürgen Bader; Felicitas Hitz; Catherine Berset; Alexandros Xyrafas; Hanne Hawle; Gregoire Berthod; Hermann S Overkleeft; Christiana Sessa; Alwin Huitema; Thomas Pabst; Roger von Moos; Dagmar Hess; Ulrich J M Mey
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

2.  Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases.

Authors:  Humaira Adnan; Zhenbo Zhang; Hyun-Joo Park; Chetankumar Tailor; Clare Che; Mustafa Kamani; George Spitalny; Beth Binnington; Clifford Lingwood
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

3.  Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.

Authors:  G P Soriano; L Besse; N Li; M Kraus; A Besse; N Meeuwenoord; J Bader; B Everts; H den Dulk; H S Overkleeft; B I Florea; C Driessen
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.